Exploring epigenetic dynamics unveils a super-enhancer-mediated NDRG1-β-catenin axis in modulating gemcitabine resistance in pancreatic cancer
Cancer Letters · 2024-11 · 605 · 217284
DOI: 10.1016/j.canlet.2024.217284 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024-11. Verfasst von Dianhui Wei und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Sha…. Hauptthemen laut MEDLINE: Gemcitabine, Deoxycytidine, Drug Resistance, Neoplasm, Pancreatic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Shanghai Municipal Natural Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Chemoresistance remains a formidable challenge in pancreatic ductal adenocarcinoma (PDAC) treatment, necessitating a comprehensive exploration of underlying molecular mechanisms. This work aims to investigate the dynamic epigenetic landscape during the development of gemcitabine resistance in PDAC, with a specific focus on super-enhancers and their regulatory effects. We employed well-established gemcitabine-resistant (Gem-R) PDAC cell lines to perform high-throughput analyses of the epigenome, enhancer connectome, and transcriptome. Our findings revealed notable alterations in the epigenetic landscape and genome architecture during the transition from gemcitabine-sensitive to -resistant PDAC cells. Remarkably, we observed substantial plasticity in the activation status of super-enhancers, with a considerable proportion of these cis-elements becoming deactivated in chemo-resistant cells. Furthermore, we pinpointed the NDRG1 super-enhancer (NDRG1-SE) as a crucial regulator in gemcitabine resistance among the loss-of-function super-enhancers. NDRG1-SE deactivation induced activation of WNT/β-catenin signaling, thereby conferring gemcitabine resistance. This work underscores a NDRG1 super-enhancer deactivation-driven β-catenin pathway activation as a crucial regulator in the acquisition of gemcitabine-resistance. These findings advance our understanding of PDAC biology and provide valuable insights for the development of effective therapeutic approaches against chemoresistance in this malignant disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200032, China.
- Institute of Theoretical Chemistry, College of Chemistry, Jilin University, Changchun, 130023, China. Electronic address: jilongzhang@jlu.edu.cn.
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200032, China. Electronic address: jingtiantian1991@126.com.
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. Electronic address: aliuyz@126.com.
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200032, China. Electronic address: wbs137@shsci.org.
Förderung
- Shanghai Municipal Natural Science Foundation
- National Natural Science Foundation of China
Zitieren
APA
Wei, D., Yuan, L., Xu, X., Wu, C., Huang, Y., Zhang, L., Zhang, J., Jing, T., Liu, Y., & Wang, B. (2024). Exploring epigenetic dynamics unveils a super-enhancer-mediated NDRG1-β-catenin axis in modulating gemcitabine resistance in pancreatic cancer. Cancer Letters, 605, 217284. https://doi.org/10.1016/j.canlet.2024.217284
Vancouver
Wei D, Yuan L, Xu X, Wu C, Huang Y, Zhang L, et al. Exploring epigenetic dynamics unveils a super-enhancer-mediated NDRG1-β-catenin axis in modulating gemcitabine resistance in pancreatic cancer. Cancer Letters. 2024;605:217284. doi:10.1016/j.canlet.2024.217284
BibTeX
@article{Wei2024,
author = {Wei, Dianhui and Yuan, Lili and Xu, Xiaoli and Wu, Chengsi and Huang, Yiwen and Zhang, Lili and Zhang, Jilong and Jing, Tiantian and Liu, Yizhen and Wang, Boshi},
title = {Exploring epigenetic dynamics unveils a super-enhancer-mediated NDRG1-β-catenin axis in modulating gemcitabine resistance in pancreatic cancer},
journal = {Cancer Letters},
year = {2024},
volume = {605},
pages = {217284},
doi = {10.1016/j.canlet.2024.217284}
}
EUVIMED